Posts

Samsung Biologics Expands into Peptide API Manufacturing with $1.8B PolyPeptide Acquisition

on

Production problems hamper Lantheus bid for FDA approval of LNTH-2501 radiopharma diagnostic kit

on

Bora snaps up MacroGenics' manufacturing, CDMO operations for up to $127.5M

on

No Recent News Found on Samsung Biologics' $102M Strike Impact

on

Agile Partnerships Drive Faster Pharma Innovation

on

Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up

on

FUJIFILM Biotechnologies Appoints Christiane Bardroff as Chief Business Officer

on

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform

on

Rezon Bio Launches Two State-of-the-Art CDMO Facilities for Biologics in Europe

on

CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling

on

National Resilience Restructures Manufacturing Footprint, Closes 6 of 10 Plants

on

Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

on

Lonza's Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand

on

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

on

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

on